La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

Identifieur interne : 003C02 ( Main/Merge ); précédent : 003C01; suivant : 003C03

Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.

Auteurs : R. Grondin [Canada] ; P J Bédard ; A. Hadj Tahar ; L. Grégoire ; A. Mori ; H. Kase

Source :

RBID : pubmed:10331698

English descriptors

Abstract

Chronic treatment with L-3,4-dihydroxyphenylalanine (L-dopa) is often associated with motor side effects in PD patients. The search for new therapeutic approaches has led to study the role of other neuromodulators including adenosine. Among the four adenosine receptors characterized so far, the A2A subtype is distinctively present on striatopallidal output neurons containing enkephalin and mainly bearing dopamine (DA) D2 receptors (indirect pathway). Studies in DA-denervated rats suggest that blockade of adenosine A2A receptors might be used in PD.

PubMed: 10331698

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:10331698

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.</title>
<author>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R" last="Grondin">R. Grondin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neuroscience Research Unit, Laval University Research Center, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuroscience Research Unit, Laval University Research Center, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P J" last="Bédard">P J Bédard</name>
</author>
<author>
<name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A" last="Hadj Tahar">A. Hadj Tahar</name>
</author>
<author>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L" last="Grégoire">L. Grégoire</name>
</author>
<author>
<name sortKey="Mori, A" sort="Mori, A" uniqKey="Mori A" first="A" last="Mori">A. Mori</name>
</author>
<author>
<name sortKey="Kase, H" sort="Kase, H" uniqKey="Kase H" first="H" last="Kase">H. Kase</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1999">1999</date>
<idno type="RBID">pubmed:10331698</idno>
<idno type="pmid">10331698</idno>
<idno type="wicri:Area/PubMed/Corpus">001712</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001712</idno>
<idno type="wicri:Area/PubMed/Curation">001712</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001712</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001712</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001712</idno>
<idno type="wicri:Area/Ncbi/Merge">000020</idno>
<idno type="wicri:Area/Ncbi/Curation">000020</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000020</idno>
<idno type="wicri:doubleKey">0028-3878:1999:Grondin R:antiparkinsonian:effect:of</idno>
<idno type="wicri:Area/Main/Merge">003C02</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.</title>
<author>
<name sortKey="Grondin, R" sort="Grondin, R" uniqKey="Grondin R" first="R" last="Grondin">R. Grondin</name>
<affiliation wicri:level="1">
<nlm:affiliation>Neuroscience Research Unit, Laval University Research Center, Quebec, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Neuroscience Research Unit, Laval University Research Center, Quebec</wicri:regionArea>
<wicri:noRegion>Quebec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Bedard, P J" sort="Bedard, P J" uniqKey="Bedard P" first="P J" last="Bédard">P J Bédard</name>
</author>
<author>
<name sortKey="Hadj Tahar, A" sort="Hadj Tahar, A" uniqKey="Hadj Tahar A" first="A" last="Hadj Tahar">A. Hadj Tahar</name>
</author>
<author>
<name sortKey="Gregoire, L" sort="Gregoire, L" uniqKey="Gregoire L" first="L" last="Grégoire">L. Grégoire</name>
</author>
<author>
<name sortKey="Mori, A" sort="Mori, A" uniqKey="Mori A" first="A" last="Mori">A. Mori</name>
</author>
<author>
<name sortKey="Kase, H" sort="Kase, H" uniqKey="Kase H" first="H" last="Kase">H. Kase</name>
</author>
</analytic>
<series>
<title level="j">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint>
<date when="1999" type="published">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)</term>
<term>Animals</term>
<term>Brain (drug effects)</term>
<term>Female</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Locomotion (drug effects)</term>
<term>Macaca fascicularis</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson Disease, Secondary (drug therapy)</term>
<term>Purinergic P1 Receptor Antagonists</term>
<term>Purines (pharmacology)</term>
<term>Purines (therapeutic use)</term>
<term>Receptor, Adenosine A2A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en">
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Brain</term>
<term>Locomotion</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Levodopa</term>
<term>Purines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Levodopa</term>
<term>Purines</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Female</term>
<term>Macaca fascicularis</term>
<term>Purinergic P1 Receptor Antagonists</term>
<term>Receptor, Adenosine A2A</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Chronic treatment with L-3,4-dihydroxyphenylalanine (L-dopa) is often associated with motor side effects in PD patients. The search for new therapeutic approaches has led to study the role of other neuromodulators including adenosine. Among the four adenosine receptors characterized so far, the A2A subtype is distinctively present on striatopallidal output neurons containing enkephalin and mainly bearing dopamine (DA) D2 receptors (indirect pathway). Studies in DA-denervated rats suggest that blockade of adenosine A2A receptors might be used in PD.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003C02 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003C02 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Merge
   |type=    RBID
   |clé=     pubmed:10331698
   |texte=   Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i   -Sk "pubmed:10331698" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022